Director Laura Brege of Mirum Pharmaceuticals, Inc. filed a Form 144 notice of proposed sale of securities on November 12, 2026, covering 14,167 shares of common stock acquired through a stock option exercise on November 11, 2026.

Key Highlights

  • Person filing: Laura Brege, Director of Mirum Pharmaceuticals, Inc.
  • Shares proposed for sale: 14,167 shares of common stock, with an aggregate market value of $1,334,673.07, according to the filing.
  • Acquisition: The 14,167 shares were acquired via a stock option exercise from the issuer on November 11, 2026, with cash payment on the same date.
  • Exchange listed: The securities trade on NASDAQ.
  • Shares outstanding: The filing reports 65,282,044 shares outstanding.
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the broker for the proposed sale.
  • Prior three-month sales: The filing states "Nothing to Report" for securities sold during the past three months.

Mirum Pharmaceuticals Director Proposes Sale Following Stock Option Exercise

According to the Form 144 filed with the U.S. Securities and Exchange Commission, Laura Brege, who serves as a Director of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), proposed the sale of 14,167 shares of common stock. The filing states the aggregate market value of those shares is $1,334,673.07, and that there were 65,282,044 shares of common stock outstanding at the time of the notice.

The filing discloses that the 14,167 shares were acquired on November 11, 2026, through a stock option exercise from the issuer, with cash paid as consideration on the same date. The approximate date of sale listed in the filing is also November 11, 2026. The filing includes a remark explaining that "Sales that were executed on November 11, 2026 are being reported on this Form 144 filed on November 12, 2026 given the EDGAR system was not accepting filings on November 11, 2026 in observance of the federal holiday."

Mirum Pharmaceuticals, Inc. is headquartered at 989 East Hillsdale Boulevard, Suite 300, Foster City, California 94404. The Form 144 carries the SEC File Number 001-38981. The filing reports no securities sold by Brege during the three months preceding this notice.

What Was Disclosed

Laura Brege, a Director at Mirum Pharmaceuticals, filed a Form 144 on November 12, 2026, proposing the sale of 14,167 common shares with an aggregate market value of $1,334,673.07, acquired via stock option exercise on November 11, 2026, through Morgan Stanley Smith Barney LLC.